Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000947871-25-000629
Filing Date
2025-06-26
Accepted
2025-06-26 17:10:11
Documents
1
Period of Report
2025-06-24

Document Format Files

Seq Description Document Type Size
1 ownership.html 4  
1 ownership.xml 4 9273
  Complete submission text file 0000947871-25-000629.txt   11532
Mailing Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022
Business Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022 (212) 739-6400
ORBIMED ADVISORS LLC (Reporting) CIK: 0001055951 (see all company filings)

State of Incorp.: DE
Type: 4 | Act: 34 | File No.: 001-39231 | Film No.: 251081241

Mailing Address 601 LEXINGTON AVENUE, 54TH FLOOR NEW YORK NY 10022
Business Address 601 LEXINGTON AVENUE, 54TH FLOOR NEW YORK NY 10022 212-739-6491
OrbiMed Capital GP VII LLC (Reporting) CIK: 0001760648 (see all company filings)

State of Incorp.: DE | Fiscal Year End: 1231
Type: 4 | Act: 34 | File No.: 001-39231 | Film No.: 251081240

Mailing Address ONE COMMERCE SQUARE 2005 MARKET STREET, 39TH FLOOR PHILADELPHIA PA 19103
Business Address ONE COMMERCE SQUARE 2005 MARKET STREET, 39TH FLOOR PHILADELPHIA PA 19103 2678660312
Passage BIO, Inc. (Issuer) CIK: 0001787297 (see all company filings)

EIN.: 822729751 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)